Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?

J Am Heart Assoc. 2020 Apr 7;9(7):e016509. doi: 10.1161/JAHA.120.016509. Epub 2020 Apr 1.
No abstract available

MeSH terms

  • Angiotensin Receptor Antagonists / adverse effects
  • Angiotensin Receptor Antagonists / pharmacology*
  • Angiotensin-Converting Enzyme 2
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Betacoronavirus / drug effects*
  • COVID-19
  • Cardiovascular Diseases* / complications
  • Cardiovascular Diseases* / drug therapy
  • Comorbidity
  • Coronavirus Infections / complications*
  • Coronavirus Infections / mortality
  • Disease Notification
  • Humans
  • Pandemics
  • Peptidyl-Dipeptidase A / drug effects
  • Peptidyl-Dipeptidase A / metabolism
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / mortality
  • Risk Factors
  • SARS-CoV-2
  • Severity of Illness Index

Substances

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2